Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.

von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R.

Lancet Respir Med. 2019 Jan 7. pii: S2213-2600(18)30426-0. doi: 10.1016/S2213-2600(18)30426-0. [Epub ahead of print]

PMID:
30630778
2.

Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.

Hafkin J, Hittel N, Martin A, Gupta R.

Eur Respir J. 2019 Jan 10;53(1). pii: 1801154. doi: 10.1183/13993003.01154-2018. Print 2019 Jan. No abstract available.

PMID:
30361253
3.

Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).

Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J.

Tuberculosis (Edinb). 2018 Jul;111:20-30. doi: 10.1016/j.tube.2018.04.008. Epub 2018 May 3. Review.

PMID:
30029909
4.

Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use.

Hafkin J, Hittel N, Martin A, Gupta R.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700311. doi: 10.1183/13993003.00311-2017. Print 2017 Jul. No abstract available.

5.

Delamanid in the treatment of multidrug-resistant tuberculosis.

Gupta R, Wells CD, Hittel N, Hafkin J, Geiter LJ.

Int J Tuberc Lung Dis. 2016 Dec 1;20(12):33-37. doi: 10.5588/ijtld.16.0125. Review.

PMID:
28240570
6.

Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis.

Gupta R, Geiter LJ, Hafkin J, Wells CD.

Int J Tuberc Lung Dis. 2015 Oct;19(10):1261-2. doi: 10.5588/ijtld.15.0541. No abstract available.

PMID:
26459547
7.

Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.

Hafkin JS, Osborn MK, Localio AR, Amorosa VK, Kostman JR, Stern JJ, De La Torre P, Mounzer K, Frank I, Gross R, Chang KM, Lo Re V 3rd.

J Viral Hepat. 2014 Apr;21(4):288-96. doi: 10.1111/jvh.12142. Epub 2013 Jul 30.

8.

Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana.

Hafkin J, Modongo C, Newcomb C, Lowenthal E, MacGregor RR, Steenhoff AP, Friedman H, Bisson GP.

Int J Tuberc Lung Dis. 2013 Mar;17(3):348-53. doi: 10.5588/ijtld.12.0100. Epub 2013 Jan 14.

9.

Drug-resistant tuberculosis in sub-saharan Africa.

Hafkin J, Gammino VM, Amon JJ.

Curr Infect Dis Rep. 2010 Jan;12(1):36-45. doi: 10.1007/s11908-009-0074-7.

PMID:
21308497
10.

Infections in lung transplantation: new insights.

Hafkin J, Blumberg E.

Curr Opin Organ Transplant. 2009 Oct;14(5):483-7. doi: 10.1097/MOT.0b013e32833062f6. Review.

PMID:
19623072

Supplemental Content

Loading ...
Support Center